DNLI FY 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M+122.9% YoY

Gross Profit

$108M100.0% margin

Operating Income

-$341M-314.2% margin

Net Income

-$326M-300.6% margin

EPS (Diluted)

$-2.60

Cash Flow

Operating Cash Flow

-$245M

Free Cash Flow

-$263M

Stock-Based Comp.

$100M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$418M

Stockholders' Equity

$1.0B

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$49M	+122.9%
Gross Profit	$108M	$49M	+122.9%
Operating Income	-$341M	-$296M	-15.2%
Net Income	-$326M	-$291M	-12.2%